论文部分内容阅读
目的:观察暖宫贴联合盐酸莫西沙星片对慢性盆腔炎临床疗效及C-反应蛋白的影响。方法:选取90例慢性盆腔炎患者,采用随机数字表法将其分为对照组与观察组各45例。对照组患者给予莫西沙星片治疗,观察组患者给予暖宫贴联合莫西沙星治疗。比较两组患者的临床疗效及治疗前后C-反应蛋白值的变化。结果:观察组患者的总有效率(95.6%)明显高于对照组(80.0%),差异有统计学意义(P<0.05)。治疗前两组患者的C-反应蛋白值差异无统计学意义(P>0.05);治疗后观察组患者C-反应蛋白值明显低于对照组,差异具有统计学意义(P<0.05)。结论:暖宫贴联合盐酸莫西沙星片治疗慢性盆腔炎疗效确切,能有效抑制盆腔炎炎性分泌物的分泌,并促进其吸收。
Objective: To observe the effect of Moxibustion combined with moxifloxacin hydrochloride on clinical efficacy and C-reactive protein in patients with chronic pelvic inflammatory disease. Methods: Ninety patients with chronic pelvic inflammatory disease were selected and randomly divided into control group and observation group with 45 cases in each group. Patients in the control group were treated with moxifloxacin tablets, while patients in the observation group were given moxifloxacin and moxifloxacin. The clinical efficacy and the changes of C-reactive protein before and after treatment were compared between the two groups. Results: The total effective rate (95.6%) in the observation group was significantly higher than that in the control group (80.0%), the difference was statistically significant (P <0.05). There was no significant difference in C-reactive protein between the two groups before treatment (P> 0.05). After treatment, the C-reactive protein in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Moxipu combined with moxifloxacin hydrochloride tablets for the treatment of chronic pelvic inflammatory disease is effective and can effectively inhibit the secretion of inflammatory secretions of pelvic inflammatory cells and promote its absorption.